Chemotherapeutic medicines can either be used alone or in combination with other treatments to treat skin cancer. These medications are administered orally or intravenously. Their dosage is solely determined by the patients' previous skin cancer therapy, as well as their tolerance levels and age.



Drugs that have been authorised to treat basal cell carcinoma include:

  • Imiquimod:

This medication is commonly used to treat advanced basal cell carcinoma, actinic keratosis, and genital warts.

  • Fluorouracil (Topical):

It is used to treat basal cell carcinomas that are resistant to surgery. Actinic keratosis is also treated with fluorouracil.

  • Vismodegib :

It is a medicine that is approved to treat locally advanced, recurring, or metastasized basal cell carcinoma that has failed to respond to surgery or radiation therapy.

  • Sonidegib:

It is a drug that is prescribed to individuals with basal cell carcinoma at any stage. A cycle of this drug is prescribed if any signs and symptoms of BCC are discovered.

Melanoma drugs that have been authorised include:

  • Dabrafenib:

When melanoma has migrated to the lymph nodes and treatment is no longer effective, this medication is administered. It is frequently taken in conjunction with trametinib to increase the likelihood of success.

  • Aldesleukin:

This medication is used to treat melanoma that has spread to other parts of the body. It is frequently prescribed to patients who have a high level of tolerance.

  • Cobimetinib:

Cobimetinib has been approved for people who have skin cancer that cannot be removed surgically. It's frequently used for skin malignancies that have spread, particularly melanoma.

  • Ipilimumab:

Ipilimumab is an adjuvant therapy for melanoma that has progressed to the lymph nodes and distant organs. It is only suggested for people above the age of 12 and for skin malignancies that cannot be removed surgically.

  • Dacarbazine

It is used to treat metastasized skin malignancies, particularly melanoma. When chemotherapy medications have failed to improve the patient's condition, it is usually prescribed.

  • Talimogene Laherparepvec:

This medicine is used to treat melanoma that has spread to the skin and lymph nodes and has not been cured by surgery. Talimogene Laherparepvec is also used to treat skin cancer that has returned after surgery. More information on skin cancer surgery can be found here.

  • Recombinant Interferon Alfa-2b:

It is an adjuvant therapy for melanoma patients to reduce pain and discomfort. It is prescribed for people who are at a higher risk of recurrence melanoma after aggressive therapies.

  • Trametinib

It is a drug that has been approved to treat both localised and metastatic melanoma that has failed to respond to surgery. To treat melanoma, trametinib is frequently used in conjunction with dabrafenib.

  • Pembrolizumab:

This medicine is approved for the treatment of metastasized melanoma that cannot be treated with surgery alone.

  • Peginterferon Alfa-2b

It is a drug that has been approved to treat metastasized melanoma that has not responded to other treatments. For cancer that has progressed to the lymph nodes, peginterferon Alfa-2b is frequently administered.

  • Vemurafenib

It is a drug used to treat melanoma that has not responded to prior treatments. It's especially useful for people whose cancer has spread to their lymph nodes.

  • Nivolumab

It is a drug that is given to people who have had their cancer treated surgically but it has spread. It's frequently used in conjunction with Ipilimumab.

Squamous cell carcinoma drugs that have been approved include:

  • Cemiplimab-rwlc is a medication that has been approved to treat localised and metastatic cutaneous squamous cell carcinoma that has not responded to prior treatments.

Combinations of drugs to treat skin cancer:

Skin cancer therapies are frequently used in conjunction with other treatments or anti-cancer medications. The following are the most regularly prescribed medication combinations for treating skin cancer:

  • Trametinib + Dabrafenib
  • Cobimetinib + Vemurafenib
  • Binimetinib + Encorafenib
  • Ipilimumab + Nivolumab